Argenx Se (ARGX) Long-Term Investments (2015 - 2025)
Argenx Se (ARGX) posted quarterly Long-Term Investments of $3.4 million for Q4 2025, down 63.55% year-on-year from $9.3 million in Q4 2024, and down 99.97% on a QoQ basis from $10.7 billion in Q2 2025.
Argenx Se (ARGX) Long-Term Investments (2015 - 2025) Analysis & Trends
Argenx Se (ARGX) has reported Long-Term Investments for 11 consecutive years, with $3.4 million the latest figure, recorded in Q4 2025.
- Quarterly Long-Term Investments fell 63.55% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (down 63.55% YoY) and the FY2025 annual result came in at -$6.5 million, down 170.13% from the prior year.
- Long-Term Investments eased to $3.4 million in Q4 2025 per ARGX's latest filing, from $10.7 billion in the prior quarter.
- Over the last five years, Long-Term Investments for ARGX reached as high as $10.7 billion in Q2 2025 and fell as low as -$370.3 million in Q2 2021.
- A 5-year average of $1.0 billion and a median of $7.9 million in 2024 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2021 — Long-Term Investments sank 223.7% — and 2025, when it surged 161757.86%.
- Year by year, Long-Term Investments stood at $76.7 million in 2021, then tumbled by 98.27% to $1.3 million in 2022, then jumped by 649.21% to $9.9 million in 2023, then fell by 6.5% to $9.3 million in 2024, then plunged by 63.55% to $3.4 million in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $3.4 million, $10.7 billion, and $9.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 22.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.38 Mn |
| Jun 30, 2025 | 10.68 Bn |
| Dec 31, 2024 | 9.27 Mn |
| Jun 30, 2024 | 6.60 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Jun 30, 2023 | 12.44 Mn |
| Dec 31, 2022 | 1.32 Mn |
| Jun 30, 2022 | -234.24 Mn |
| Dec 31, 2021 | 76.66 Mn |
| Jun 30, 2021 | -370.34 Mn |
| Dec 31, 2020 | 5.85 Mn |
| Jun 30, 2020 | 299.38 Mn |
| Dec 31, 2019 | 2.95 Mn |
| Jun 30, 2019 | -555.93 Mn |
| Mar 31, 2019 | 23.90 Mn |
| Dec 31, 2018 | 1,137.95 |
| Jun 30, 2018 | -41.96 Mn |
| Dec 31, 2017 | 1,443.21 |
| Jun 30, 2017 | -131.43 Mn |
| Dec 31, 2016 | 1,443.21 |